Microchipping the breast: an effective new technology for localizing non-palpable breast lesions for surgery

• Published in: Breast cancer research and treatment 2019-05, Vol.175 (1), p.165-170
• Main Authors: DiNome, Maggie L., Kusske, Amy M., Attai, Deanna J., Fischer, Cheryce P., Hoyt, Anne C.
• Format: Article
• Language: English
• Subjects: Biopsy; Breast; Breast cancer; Cancer; Cancer research; Clinical Trial; FDA approval; Feasibility studies; Invasiveness; Localization; Mammography; Medical research; Medicine; Medicine & Public Health; Migration; NCT; NCT03202472; Oncology; Patients; Physicians; Seeds; Skin; Surgeons; Surgery; Surgical outcomes; Technology; Wire
• ISSN: 0167-6806; 1573-7217
• DOI: 10.1007/s10549-019-05143-w

Purpose Use of a wire to localize a non-palpable breast lesion for surgery is standard but archaic. We sought to evaluate a new radiofrequency localization system (RFLS) as an effective, non-radioactive alternative to the wire. Methods Patients who required surgical excision of a non-palpable breast lesion were consented for the study. Patients underwent localization with a radiofrequency Tag and surgical removal guided by the handheld LOCalizer probe. The primary study endpoint was successful placement and retrieval of the Tag, and secondary endpoints included marker migration; days prior to surgery of Tag insertion; patient, radiologist, and surgeon experience; distance of Tag from skin; and positive margin and re-excision rates for cancer. Results Fifty patients had successful placement and retrieval of the radiofrequency Tag. Likert questionnaire data revealed that most patients thought the procedure went smoothly and was easier than expected. Radiologists and surgeons thought that the Tag was as reliable as the wire. Of the 33 patients who had surgery for in situ or invasive cancer, one had a positive margin on final pathology (3%) and two underwent re-excision (6%). Conclusions Data from this pilot study suggest that the RFLS is an effective localization system for non-palpable breast lesions intended for surgical removal. Unlike most other technologies, the LOCalizer probe detects distance from the Tag, and this unique feature may have contributed to the low positive margin rate seen in this study. The RFLS appears to offer advantages over current localization procedures and should be explored as an alternative to wire. ClinicalTrials.gov Identifier: NCT03202472.